Lonza and Sidewinder Forge Alliance for Next-Generation Cancer Drugs

AMSTERDAM and SAN DIEGO – January 07, 2026 – In a significant move to advance the next frontier of cancer therapy, Lonza's Synaffix and the biotech startup Sidewinder Therapeutics have entered into a multi-target licensing agreement. The collaboration aims to develop a new class of highly precise cancer-killing molecules known as bispecific antibody-drug conjugates (ADCs) specifically designed to combat challenging solid tumors.

This partnership combines Sidewinder's innovative bispecific antibodies with Synaffix's clinically validated ADC technology platform. The goal is to create therapies that are not only more effective at destroying cancer cells but also significantly safer for patients by minimizing damage to healthy tissue—a persistent challenge in oncology. Under the agreement, Sidewinder gains access to Lonza's complete ADC toolkit, positioning the San Diego-based startup to accelerate its pipeline, with plans to initiate a clinical trial for its first candidate in 2026.

A Strategic Play in a Red-Hot Market

The ADC market is one of the most dynamic and rapidly growing sectors in biotechnology. Valued at nearly $12 billion in 2024, the market is projected to surge to over $30 billion by 2033, fueled by major clinical successes and a wave of investment. ADCs function like biological guided missiles, combining the targeting precision of an antibody with the potent cell-killing power of a chemotherapy payload. This allows for the direct delivery of toxins to cancer cells, sparing the rest of the body from widespread side effects.

This deal highlights a key trend: the evolution toward bispecific ADCs. While traditional ADCs target a single protein on a cancer cell's surface, bispecific ADCs are engineered to recognize and bind to two different targets simultaneously. This dual-targeting mechanism can dramatically increase tumor specificity, ensuring the drug only activates when it finds a unique signature present on cancer cells, not on healthy ones. It also has the potential to enhance the drug's internalization into the tumor cell, making the payload more effective.

The collaboration is a strategic masterstroke for both parties. For Lonza, which acquired Synaffix in June 2023 for an initial €100 million, it validates the strength of its integrated bioconjugation services and proprietary technologies. For Sidewinder, a young company founded in 2023 with Series A funding from the prominent healthcare investor OrbiMed, this partnership provides access to a proven, clinical-stage technology platform, significantly de-risking and accelerating its development timeline.

"The ADC field has reached an exciting moment fueled by multiple technology breakthroughs that enable the next generation of bispecific ADC innovation," said Eric Murphy, PhD, Co–Founder and Chief Executive Officer of Sidewinder Therapeutics, in the official announcement. He emphasized the synergy of combining Sidewinder's approach with Synaffix's platform to improve tolerability and patient benefit.

The Synergy of Two Advanced Platforms

The power of this collaboration lies in the complementary nature of the two companies' technologies. Sidewinder brings to the table a pipeline of bispecific antibodies designed to target unique "tumor-specific receptor complexes"—pairs of proteins that appear together primarily on cancer cells. This forms the highly specific guidance system for the therapeutic.

Lonza's Synaffix provides the critical warhead and delivery components. The license grants Sidewinder access to a trio of proprietary, clinically validated technologies:

• GlycoConnect®: A site-specific conjugation technology that attaches the drug payload to a precise, predetermined location on the antibody. This chemoenzymatic process creates highly uniform and stable ADCs, avoiding the heterogeneous mixtures produced by older methods that often led to unpredictable efficacy and toxicity.
• HydraSpace®: A polar spacer technology that links the antibody and the payload. It is designed to improve the ADC's solubility and stability, particularly when using highly potent but hydrophobic payloads, which can otherwise clump together and perform poorly.
• toxSYN®: A portfolio of potent linker-payloads. This gives Sidewinder a choice of different cytotoxic agents, including powerful topoisomerase inhibitors and microtubule inhibitors, allowing them to select the most effective "warhead" for the specific cancer type being targeted.

Peter van de Sande, Head of Synaffix at Lonza, commented on the potential of the joint effort, stating, "This collaboration brings together two cutting-edge platforms to enhance the therapeutic index of bispecific ADCs by minimizing impact on healthy tissue. We are confident that our technologies will help Sidewinder's pipeline reach its full potential."

The Path Forward: From Lab Bench to Patient Bedside

While the scientific premise is compelling, the journey from a licensing deal to an approved therapy is long and arduous. Solid tumors, in particular, present formidable challenges, including a dense and often inhibitory tumor microenvironment that can prevent drugs from reaching their target. However, the enhanced specificity and internalization promised by Sidewinder and Synaffix's combined approach are designed to overcome exactly these hurdles.

The financial structure of the deal—involving undisclosed upfront payments followed by substantial clinical, regulatory, and commercial milestones, plus royalties—is typical for early-stage biotech partnerships. It reflects a shared-risk, shared-reward model that has become the standard in an industry where the path to success is uncertain. The overall value of such deals can be substantial, with recent ADC licensing agreements in the oncology space reaching into the billions of dollars in potential milestone payments.

Sidewinder's ambitious plan to enter the clinic in 2026 will be a critical first test. Historically, the success rate for oncology drugs progressing from Phase 1 trials to market approval is low. Yet, there is reason for optimism. Data has shown that ADCs using certain payloads offered by Synaffix, such as topoisomerase inhibitors, have achieved higher overall response rates in heavily pretreated patients compared to other payload types.

This partnership represents a calculated and sophisticated bet on the future of precision oncology. By combining a novel targeting strategy with a state-of-the-art conjugation and payload platform, Lonza's Synaffix and Sidewinder Therapeutics are aiming to develop therapies that could one day offer new hope for patients with some of the most difficult-to-treat cancers.